Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDO study: Rheumatoid arthritis retreatment with ultra-low dose rituximab
2016-002908-15Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Change in DAS28-CRP from baseline. Started Aug 2016; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-002908-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002908-15.